"Anticoagulation Therapy" ed. by Ozcan Basaran and Murat Biteker

This volume is dedicated to the available parenteral and oral anticoagulants that have a large clinical use.

Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.

Contents
Preface
1 Biochemistry and Stereochemistry of Anticoagulants
2 Comparative Biology of the Resistance to Vitamin K Antagonists: An Overview of the Resistance Mechanisms
3 The Risk Factors of Thrombogenic, Thrombophilia, and the Principle for Heparin Prophylaxis in Personalized Medicine
4 Management of Anticoagulation Around Cardiac Implantable Electronic Device Surgery
5 Prothrombin Complex Concentrate, a General Antidote for Oral Anticoagulation
6 Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Pharmacology and Phase III Clinical Trials
7 Non–Vitamin K Antagonist Oral Anticoagulants, Clinical Use, Real-World Data, and Reversal of Anticoagulant Effect